Original Papers- AOKI Masashi -
number of results to view: what to display: sort:
total:365
[2017]
21.A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis.[Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration,18,(2017),11-19]Koji Abe, Yasuto Itoyama, Shoji Tsuji, Gen Sobue, Masashi Aoki, Manabu Doyu, Chikuma Hamada, Masanori Togo, Masanori Togo, Takatomo Yoneoka, Masahiko Tanaka, Makoto Akimoto, Kazue Nakamura, Fumihiro Takahashi, Kazuoki Kondo, Hiide Yoshino
10.1080/21678421.2017.1363780
http://www.ncbi.nlm.nih.gov/pubmed/28872917 http://www.scopus.com/inward/record.url?eid=85029211000&partnerID=40
22.Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.[Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration,18,(2017),20-31]Koji Abe, Yasuto Itoyama, Shoji Tsuji, Gen Sobue, Masashi Aoki, Manabu Doyu, Chikuma Hamada, Hidenao Sasaki, Asako Takei, Isao Yamashita, Takashi Imai, Imaharu Nakano, Koichi Okamoto, Yuichi Maruki, Shuichi Mishima, Jin Nishimiya, Yasuo Iwasaki, Mineo Yamazaki, Yuji Takahashi, Mieko Ogino, Yutaka Ogino, Masafumi Ogawa, Tetsumasa Kamei, Tsuyoshi Uchiyama, Hirohisa Watanabe, Yasumasa Kokubo, Hideyuki Sawada, Takanori Hazama, Fumiharu Kimura, Harutoshi Fujimura, Hirofumi Kusaka, Tsukasa Hashimoto, Takeshi Yamada, Yuji Kanamori, Kenji Yamasaki, Shizuma Kaku, Hitoshi Kikuchi, Shigehiro Imamura, Seiichiro Sugimoto, Masahiko Kishi, Masahiko Tanaka, Makoto Akimoto, Kazue Nakamura, Hiroshi Naito, Aiko Murakami, Hajime Sakamoto, Takatomo Yoneoka, Katsuyuki Enjoji, Junko Ogawa, Kiyoe Yano, Makiko Yashiro, Manabu Hirai, Keiko Furuta, Kouichi Sasaki, Youichi Shiide, Gen Takayanagi, Fumihiro Takahashi, Tomohisa Iwasaki, Kazuoki Kondo, Hiide Yoshino
10.1080/21678421.2017.1362000
http://www.ncbi.nlm.nih.gov/pubmed/28872918 http://www.scopus.com/inward/record.url?eid=85029215128&partnerID=40
23.Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).[Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration,18,(2017),40-48]Koji Abe, Yasuto Itoyama, Masashi Aoki, Shoji Tsuji, Gen Sobue, Manabu Doyu, Chikuma Hamada, Shizuki Doi, Katsuhisa Ogata, Kouichi Mizoguchi, Ikuko Aiba, Hidenori Matsuo, Masahiko Tanaka, Makoto Akimoto, Kazue Nakamura, Rie Sumii, Takatomo Yoneoka, Katsuyuki Enjoji, Makiko Yashiro, Fumihiro Takahashi, Tomohisa Iwasaki, Kazuoki Kondo, Hiide Yoshino
10.1080/21678421.2017.1361441
http://www.ncbi.nlm.nih.gov/pubmed/28872915 http://www.scopus.com/inward/record.url?eid=85029231703&partnerID=40
24.Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.[Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration,18,(2017),55-63]Koji Abe, Masashi Aoki, Shoji Tsuji, Yasuto Itoyama, Gen Sobue, Masanori Togo, Masanori Togo, Chikuma Hamada, Hidenao Sasaki, Ichiro Yabe, Shizuki Doi, Hitoshi Warita, Takashi Imai, Hiroaki Ito, Mitsumasa Fukuchi, Etsuko Osumi, Manabu Wada, Imaharu Nakanoy, Mitsuya Morita, Katsuhisa Ogata, Yuichi Maruki, Kimiko Ito, Osamu Kano, Mineo Yamazaki, Yuji Takahashi, Hiroyuki Ishiura, Mieko Ogino, Ryoko Koike, Chiho Ishida, Tsuyoshi Uchiyama, Koichi Mizoguchi, Tomokazu Obi, Hirohisa Watanabe, Naoki Atsuta, Ikuko Aiba, Akira Taniguchi, Hideyuki Sawada, Takanori Hazama, Harutoshi Fujimura, Hirofumi Kusaka, Takenobu Kunieda, Hitoshi Kikuchi, Hidenori Matsuo, Hidetsugu Ueyama, Kazutoshi Uekawa, Masahiko Tanaka, Makoto Akimoto, Kazue Nakamura, Masaki Ueda, Kuniko Kotani, Hiroshi Matsui, Takatomo Yoneoka, Kazunori Morimoto, Kouichi Sasaki, Manabu Hirai, Aiko Murakami, Tomoko Natori, Rie Sumii, Hidetomo Terai, Takuya Kudou, Fumihiro Takahashi, Tomohisa Iwasaki, Kazuoki Kondo, Hiide Yoshino
10.1080/21678421.2017.1364269
http://www.ncbi.nlm.nih.gov/pubmed/28872920 http://www.scopus.com/inward/record.url?eid=85029231382&partnerID=40
25.Questionnaire survey on the process of specialty training in neurology in Japan..[Rinsho shinkeigaku = Clinical neurology,57(7),(2017),402-410]Sonoo M, Nishiyama K, Ando T, Shindo K, Kanda T, Aoki M, Kamei S, Kikuchi S, Kusunoki S, Suzuki N, Sobue G, Nakashima K, Hara H, Hirata K, Mizusawa H, Murai H, Murata M, Mochizuki H, Takahashi R, Kira JI
10.5692/clinicalneurol.cn-001061
http://www.ncbi.nlm.nih.gov/pubmed/28637938
26.Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.[The Lancet Neurology,16,(2017),505-512]Koji Abe, Masashi Aoki, Shoji Tsuji, Yasuto Itoyama, Gen Sobue, Masanori Togo, Chikuma Hamada, Masahiko Tanaka, Makoto Akimoto, Kazue Nakamura, Fumihiro Takahashi, Kazuoki Kondo, Hiide Yoshino
10.1016/S1474-4422(17)30115-1
http://www.ncbi.nlm.nih.gov/pubmed/28522181 http://www.scopus.com/inward/record.url?eid=85019648824&partnerID=40
27.Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies..[Journal of neurology, neurosurgery, and psychiatry,88(6),(2017),534-536]Fujimori J, Takai Y, Nakashima I, Sato DK, Takahashi T, Kaneko K, Nishiyama S, Watanabe M, Tanji H, Kobayashi M, Misu T, Aoki M, Fujihara K
10.1136/jnnp-2016-315094
http://www.ncbi.nlm.nih.gov/pubmed/28209651
28.Early fast-acting treatment strategy against generalized myasthenia gravis.[Muscle and Nerve,55,(2017),794-801]Kimiaki Utsugisawa, Yuriko Nagane, Tetsuya Akaishi, Yasushi Suzuki, Tomihiro Imai, Emiko Tsuda, Naoya Minami, Akiyuki Uzawa, Naoki Kawaguchi, Masayuki Masuda, Shingo Konno, Hidekazu Suzuki, Hiroyuki Murai, Masashi Aoki
10.1002/mus.25397
http://www.ncbi.nlm.nih.gov/pubmed/27603432 http://www.scopus.com/inward/record.url?eid=85013113051&partnerID=40
29.Membrane Trafficking Illuminates a Path to Parkinson's Disease..[The Tohoku journal of experimental medicine,242(1),(2017),63-76]Hasegawa T, Sugeno N, Kikuchi A, Baba T, Aoki M
10.1620/tjem.242.63
http://www.ncbi.nlm.nih.gov/pubmed/28539529
30.Comprehensive targeted next-generation sequencing in Japanese familial amyotrophic lateral sclerosis..[Neurobiology of aging,53,(2017),194.e1-194.e8]Nishiyama A, Niihori T, Warita H, Izumi R, Akiyama T, Kato M, Suzuki N, Aoki Y, Aoki M
10.1016/j.neurobiolaging.2017.01.004
http://www.ncbi.nlm.nih.gov/pubmed/28160950
31.Whole brain and grey matter volume of Japanese patients with multiple sclerosis..[Journal of neuroimmunology,306,(2017),68-75]Akaishi T, Nakashima I, Mugikura S, Aoki M, Fujihara K
10.1016/j.jneuroim.2017.03.009
http://www.ncbi.nlm.nih.gov/pubmed/28385190
32.Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis..[Annals of neurology,81(4),(2017),512-525]Tawara N, Yamashita S, Zhang X, Korogi M, Zhang Z, Doki T, Matsuo Y, Nakane S, Maeda Y, Sugie K, Suzuki N, Aoki M, Ando Y
10.1002/ana.24919
http://www.ncbi.nlm.nih.gov/pubmed/28318044
33.MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy..[Neurology(R) neuroimmunology & neuroinflammation,4(2),(2017),e322-]Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, Sato DK, Nishiyama S, Misu T, Kuroda H, Aoki M, Fujihara K
10.1212/NXI.0000000000000322
http://www.ncbi.nlm.nih.gov/pubmed/28105459
34.Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study..[BMJ open,7(2),(2017),e013278-]Nagane Y, Murai H, Imai T, Yamamoto D, Tsuda E, Minami N, Suzuki Y, Kanai T, Uzawa A, Kawaguchi N, Masuda M, Konno S, Suzuki H, Aoki M, Utsugisawa K
10.1136/bmjopen-2016-013278
http://www.ncbi.nlm.nih.gov/pubmed/28235967
35.Longitudinal study of cognitive and cerebral metabolic changes in Parkinson's disease..[Journal of the neurological sciences,372,(2017),288-293]Baba T, Hosokai Y, Nishio Y, Kikuchi A, Hirayama K, Suzuki K, Hasegawa T, Aoki M, Takeda A, Mori E
10.1016/j.jns.2016.11.068
http://www.ncbi.nlm.nih.gov/pubmed/28017230
36.Altered Tau Isoform Ratio Caused by Loss of FUS and SFPQ Function Leads to FTLD-like Phenotypes..[Cell reports,18(5),(2017),1118-1131]Ishigaki S, Fujioka Y, Okada Y, Riku Y, Udagawa T, Honda D, Yokoi S, Endo K, Ikenaka K, Takagi S, Iguchi Y, Sahara N, Takashima A, Okano H, Yoshida M, Warita H, Aoki M, Watanabe H, Okado H, Katsuno M, Sobue G
10.1016/j.celrep.2017.01.013
http://www.ncbi.nlm.nih.gov/pubmed/28147269
37.DnaJ/Hsp40 Family and Parkinson's Disease..[Frontiers in neuroscience,11,(2017),743-]Hasegawa T, Yoshida S, Sugeno N, Kobayashi J, Aoki M
10.3389/fnins.2017.00743
http://www.ncbi.nlm.nih.gov/pubmed/29367843
[2016]
38.Questionnaire survey on recruitment for Japanese Neurology Society..[Rinsho shinkeigaku = Clinical neurology,56(12),(2016),866-872]Nishiyama K, Amano T, Aoki M, Inuzuka T, Taniwaki T, Toyoshima I, Hashimoto Y, Fukutake T, Yoshii F, Ando Y
10.5692/clinicalneurol.cn-000949
http://www.ncbi.nlm.nih.gov/pubmed/27890883
39.Tardily accelerated neurologic deterioration in two-step thallium intoxication..[Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,34,(2016),234-236]Kuroda H, Mukai Y, Nishiyama S, Takeshita T, Tateyama M, Takeda A, Aoki M
10.1016/j.jocn.2016.09.003
http://www.ncbi.nlm.nih.gov/pubmed/27692615
40.Response to treatment of myasthenia gravis according to clinical subtype..[BMC neurology,16(1),(2016),225-]Akaishi T, Suzuki Y, Imai T, Tsuda E, Minami N, Nagane Y, Uzawa A, Kawaguchi N, Masuda M, Konno S, Suzuki H, Murai H, Aoki M, Utsugisawa K
10.1186/s12883-016-0756-3
http://www.ncbi.nlm.nih.gov/pubmed/27855632
Pageļ¼š [prev] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [next]
BackTop
copyright(c)2005 Tohoku University